Effectiveness of nifedipine and deflazacort in the management of distal ureter stones

Citation
F. Porpiglia et al., Effectiveness of nifedipine and deflazacort in the management of distal ureter stones, UROLOGY, 56(4), 2000, pp. 579-582
Citations number
22
Categorie Soggetti
Urology & Nephrology
Journal title
UROLOGY
ISSN journal
00904295 → ACNP
Volume
56
Issue
4
Year of publication
2000
Pages
579 - 582
Database
ISI
SICI code
0090-4295(200010)56:4<579:EONADI>2.0.ZU;2-0
Abstract
Objectives. To evaluate the effectiveness of medical therapy during watchfu l waiting in patients with distal ureter stones. Methods. Ninety-six patients with radiopaque stones located in the distal t ract of the ureter and with stone sizes of 1 cm or smaller were involved in the study. The patients were randomly divided into two groups. Group A (n = 48) received oral treatment with 30 mg of deflazacort daily (maximum 10 d ays) plus 30 mg of slow-release nifedipine daily (maximum 4 weeks). Group B (n = 48) underwent a wait-and-watch approach. Both groups of patients were allowed to use diclofenac on demand. Statistical analyses were carried out using Student's t test, the chi-square test, and Fisher's exact test. Results. The average stone size was 5.8 +/- 1.8 mm for group A and 5.5 +/- 1.4 mm for group B. No statistically significant difference was found in st one size. Stone expulsion was observed in 38 (79%) of 48 patients in group A and in 17 (35%) of 48 patients in group B. The average expulsion time was 7 days (range 2 to 10) for group A and 20 days (range 10 to 28) for group B. A statistically significant difference was observed in both the expulsio n rate and the expulsion time (P <0.05). The mean amount of sodium diclofen ac used was 15 mg per patient for group A and 105 mg per patient for group B (P <0.05). Conclusions. The medical treatment proved to be effective and safe, as demo nstrated by the increased stone expulsion rate, decreased expulsion time, a nd reduced need for analgesic therapy. UROLOGY 56: 579-583, 2000. (C) 2000, Elsevier Science Inc.